Just a moment...
Generate professional replies to Show Cause Notices, assessment orders, audit objections, and other legal communications using TaxTMI's AI Drafter.
Step 1 – Issue Identification & Review
The AI analyses your query, notice, order, or uploaded documents and identifies the key issues involved.
• Review the issues identified by the AI
• Add, edit, remove, or refine issues as required
Step 2 – Draft Generation
Once you approve the issues, the AI performs issue-wise legal research and prepares a structured draft response.
• Relevant statutory provisions
• Judicial precedents and Supreme Court, High Court and other citations
• Issue-wise legal analysis
• Practical arguments and supporting content
• Professionally structured draft ready for further review. 
Press 'Enter' to add multiple search terms. Rules for Better Search
Use comma for multiple locations.
---------------- For section wise search only -----------------
Accuracy Level ~ 90%
Press 'Enter' after typing page number.
Press 'Enter' after typing page number.
No Folders have been created
Are you sure you want to delete "My most important" ?
NOTE:
Press 'Enter' after typing page number.
Press 'Enter' after typing page number.
Don't have an account? Register Here
Press 'Enter' after typing page number.
Issues: Whether converting enzyme blend powder into tablets and putting them into strips amounts to manufacture.
Analysis: The relevant test was whether the processing brought into existence a new and distinct product with a different name, character or commercial use under Section 2(f) of the Central Excise Act, 1944. The majority held that the powder was merely compacted into tablets for convenience and marketability, without addition of any material or any real change in identity. It was found that the product did not lose its essential identity and that the conversion into tablets, on the facts, did not create a new commodity. The presence of a specific deeming note in another chapter was held not to compel the opposite result for the chapter in question.
Conclusion: Conversion of enzyme blend powder into tablets did not amount to manufacture, and the appeal succeeded.